Drug Database · Clinicians

Atracurium

Brands (24) Atravell, Acurium, Agletrium…Show all

US brand (reference label): Atracurium Besylate; not a Philippine-registered brand.

Muscle relaxant (other quaternary ammonium compounds); Muscle relaxant, peripherally acting agent; and others PH FDA category

Rx · Prescription drug26 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID efe90ee2-fe9e-421f-9e54-2961085d3b12, version date December 4, 2024 (Atracurium Besylate · Meitheal Pharmaceuticals Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Contraindications

CONTRAINDICATIONS Atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. Use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION To avoid distress to the patient, atracurium should not be administered before unconsciousness has been induced. Atracurium should not be mixed in the same syringe, or administered simultaneously through the same needle, with alkaline solutions (e.g., barbiturate solutions). Atracurium besylate should be administered intravenously.

DO NOT GIVE ATRACURIUM BESYLATE BY INTRAMUSCULAR ADMINISTRATION. Intramuscular administration of atracurium besylate may result in tissue irritation and there are no clinical data to support this route of administration. As with other neuromuscular blocking agents, the use of a peripheral nerve stimulator will permit the most advantageous use of atracurium besylate, minimizing the possibility of overdosage or underdosage, and assist in the evaluation of recovery.

Bolus Doses for Intubation and Maintenance of Neuromuscular Block Adults An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED 95), given as an intravenous bolus injection, is the recommended initial dose for most patients. With this dose, good or excellent conditions for nonemergency intubation can be expected in 2 to 2.5 minutes in most patients, with maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.

Clinically required neuromuscular block generally lasts 20 to 35 minutes under balanced anesthesia. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 minutes after injection. Atracurium is potentiated by isoflurane or enflurane anesthesia.

The same initial atracurium besylate dose of 0.4 to 0.5 mg/kg may be used for intubation prior to administration of these inhalation agents; however, if atracurium is first administered under steady-state of isoflurane or enflurane, the initial atracurium besylate dose should be reduced by approximately one-third, i.e., to 0.25 to 0.35 mg/kg, to adjust for the potentiating effects of these anesthetic agents. With halothane, which has only a marginal (approximately 20%) potentiating effect on atracurium, smaller dosage reductions may be considered.

Atracurium besylate doses of 0.08 to 0.10 mg/kg are recommended for maintenance of neuromuscular block during prolonged surgical procedures. The first maintenance dose will generally be required 20 to 45 minutes after the initial atracurium besylate injection, but the need for maintenance doses should be determined by clinical criteria.

Because atracurium lacks cumulative effects, maintenance doses may be administered at relatively regular intervals for each patient, ranging approximately from 15 to 25 minutes under balanced anesthesia, slightly longer under isoflurane or enflurane. Higher atracurium doses (up to 0.2 mg/kg) permit maintenance dosing at longer intervals.

Pediatric Patients No atracurium dosage adjustments are required for pediatric patients two years of age or older. An atracurium besylate dose of 0.3 to 0.4 mg/kg is recommended as the initial dose for infants (1 month to 2 years of age) under halothane anesthesia. Maintenance doses may be required with slightly greater frequency in infants and children than in adults.

Special Considerations An initial atracurium besylate dose of 0.3 to 0.4 mg/kg, given slowly or in divided doses over one minute, is recommended for adults, children, or infants with significant cardiovascular disease and for adults, children, or infants with any history (e.g., severe anaphylactoid reactions or asthma) suggesting a greater risk of histamine release. Dosage reductions must be considered also in patients with neuromuscular disease, severe electrolyte disorders, or carcinomatosis in which potentiation of neuromuscular block or difficulties with reversal have been demonstrated.

There has been no clinical experience with atracurium in these patients, and no specific dosage adjustments can be recommended. No atracurium dosage adjustments are required for patients with renal disease. An initial atracurium besylate dose of 0.3 to 0.4 mg/kg is recommended for adults following the use of succinylcholine for intubation under balanced anesthesia.

Further reductions may be desirable with the use of potent inhalation anesthetics. The patient should be permitted to recover from the effects of succinylcholine prior to atracurium administration. Insufficient data are available for recommendation of a specific initial atracurium dose for administration following the use of succinylcholine in children and infants.

Use by Continuous Infusion Infusion in the Operating Room (OR) After administration of a recommended initial bolus dose of atracurium besylate injection (0.3 to 0.5 mg/kg), a diluted solution of atracurium besylate can be administered by continuous infusion to adults and pediatric patients aged 2 or more years for maintenance of neuromuscular block during extended surgical procedures. Infusion of atracurium should be individualized for each patient.

The rate of administration should be adjusted according to the patient's response as determined by peripheral nerve stimulation. Accurate dosing is best achieved using a precision infusion device. Infusion of atracurium should be initiated only after early evidence of spontaneous recovery from the bolus dose. An initial infusion rate of 9 to 10 mcg/kg/min may be required to rapidly counteract the spontaneous recovery of neuromuscular function.

Thereafter, a rate of 5 to 9 mcg/kg/min should be adequate to maintain continuous neuromuscular block in the range of 89% to 99% in most pediatric and adult patients under balanced anesthesia. Occasional patients may require infusion rates as low as 2 mcg/kg/min or as high as 15 mcg/kg/min. The neuromuscular blocking effect of atracurium administered by infusion is potentiated by enflurane or isoflurane and, to a lesser extent, by halothane.

Reduction in the infusion rate of atracurium should, therefore, be considered for patients receiving inhalation anesthesia. The rate of atracurium infusion should be reduced by approximately one-third in the presence of steady-state enflurane or isoflurane anesthesia; smaller reductions should be considered in the presence of halothane.

In patients undergoing cardiopulmonary bypass with induced hypothermia, the rate of infusion of atracurium required to maintain adequate surgical relaxation during hypothermia (25° to 28°C) has been shown to be approximately half the rate required during normothermia. Spontaneous recovery from neuromuscular block following discontinuation of atracurium infusion may be expected to proceed at a rate comparable to that following administration of a single bolus dose.

Infusion in the Intensive Care Unit (ICU) The principles for infusion of atracurium in the OR are also applicable to use in the ICU. An infusion rate of 11 to 13 mcg/kg/min (range: 4.5 to 29.5) should provide adequate neuromuscular block in adult patients in an ICU. Limited information suggests that infusion rates required for pediatric patients in the ICU may be higher than in adult patients.

There may be wide interpatient variability in dosage requirements and these requirements may increase or decrease with time (see PRECAUTIONS, Long-Term Use in Intensive Care Unit (ICU)). Following recovery from neuromuscular block, readministration of a bolus dose may be necessary to quickly re-establish neuromuscular block prior to reinstitution of the infusion.

Infusion Rate Tables The amount of infusion solution required per minute will depend upon the concentration of atracurium in the infusion solution, the desired dose of atracurium, and the patient's weight. The following tables provide guidelines for delivery, in mL/hr (equivalent to microdrops/min when 60 microdrops = 1 mL), of atracurium solutions in concentrations of 0.2 mg/mL (20 mg in 100 mL) or 0.5 mg/mL (50 mg in 100 mL) with an infusion pump or a gravity flow device.

Table 3: Atracurium Besylate Infusion Rates for a Concentration of 0.2 mg/mL Patient Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 6 7 8 9 10 11 12 13 Infusion Delivery Rate (mL/hr) 30 45 54 63 72 81 90 99 108 117 35 53 63 74 84 95 105 116 126 137 40 60 72 84 96 108 120 132 144 156 45 68 81 95 108 122 135 149 162 176 50 75 90 105 120 135 150 165 180 195 55 83 99 116 132 149 165 182 198 215 60 90 108 126 144 162 180 198 216 234 65 98 117 137 156 176 195 215 234 254 70 105 126 147 168 189 210 231 252 273 75 113 135 158 180 203 225 248 270 293 80 120 144 168 192 216 240 264 288 312 90 135 162 189 216 243 270 297 324 351 100 150 180 210 240 270 300 330 360 390 Table 4: Atracurium Besylate Infusion Rates for a Concentration of 0.5 mg/mL Patient Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 6 7 8 9 10 11 12 13 Infusion Delivery Rate (mL/hr) 30 18 22 25 29 32 36 40 43 47 35 21 25 29 34 38 42 46 50 55 40 24 29 34 38 43 48 53 58 62 45 27 32 38 43 49 54 59 65 70 50 30 36 42 48 54 60 66 72 78 55 33 40 46 53 59 66 73 79 86 60 36 43 50 58 65 72 79 86 94 65 39 47 55 62 70 78 86 94 101 70 42 50 59 67 76 84 92 101 109 75 45 54 63 72 81 90 99 108 117 80 48 58 67 77 86 96 106 115 125 90 54 65 76 86 97 108 119 130 140 100 60 72 84 96 108 120 132 144 156 Compatibility and Admixtures Atracurium besylate infusion solutions may be prepared by admixing atracurium besylate injection with an appropriate diluent such as 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection. Infusion solutions should be used within 24 hours of preparation.

Unused solutions should be discarded. Solutions containing 0.2 mg/mL or 0.5 mg/mL atracurium besylate in the above diluents may be stored either under refrigeration or at room temperature for 24 hours without significant loss of potency. Care should be taken during admixture to prevent inadvertent contamination. Visually inspect prior to administration.

Spontaneous degradation of atracurium besylate has been demonstrated to occur more rapidly in Lactated Ringer's solution than in 0.9% sodium chloride solution. Therefore, it is recommended that Lactated Ringer's Injection not be used as a diluent in preparing solutions of atracurium besylate injection for infusion. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Risk of Medication Errors Accidental administration of neuromuscular blocking agents may be fatal. Store atracurium besylate injection with the cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product.

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

No atracurium dosage adjustments are required for patients with renal disease.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in pediatric patients below the age of 1 month have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Since marketing in 1983, uncontrolled clinical experience and limited data from controlled trials have not identified differences in effectiveness, safety, or dosage requirements between healthy elderly and younger patients (see CLINICAL PHARMACOLOGY); however, as with other neuromuscular blocking agents, the use of a peripheral nerve stimulator to monitor neuromuscular function is suggested (see DOSAGE AND ADMINISTRATION).

Dosage forms

Philippines

  • Solution for injection: 10 mg/mL
  • ) solution for injection: 10 mg/mL (25 mg/2.5 mL, 10 mg/mL (25 mg/2.5 mL) (50 mg/5 mL, 10 mg/mL (50 mg/5 mL
  • ) solution for injection for i.v. infusion: 10 mg/mL (25 mg/2.5 mL and 50 mg/5 mL
  • ) solution for iv infusion: 10 mg/mL (25 mg/2.5 mL and 50 mg/5 mL
  • ) solution for iv injection/infusion: 10 mg/mL (25 mg/2.5 mL
  • Solution for i.v injection: 10 mg/mL
  • Solution for injection iv): 10 mg/mL

Registered products in the Philippines

26 products registered with the Food and Drug Administration (FDA) Philippines list Atracurium as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products26
Philippine FDA-registered products for Atracurium
Package insert
AcuriumAtracurium Besilate
10 mg/mL Solution for Injection (I.V.)USP Type I Glass Ampoule x 2.5 mL (Box of 5's)
Rx
Swiss Parenterals, Ltd.India
Endure Medical, Inc.
DR-XY41413
Nov 19, 2027
AgletriumAtracurium besilate
10 mg/mL Solution for Injection (IV)USP Type I Glass Ampoule x 2.5 mL and 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
FADZ PHARMA INC.Importer: Ambica International Corporation
DRP-7642-02
Oct 8, 2029
Atra-CureAtracurium Besilate
10 mg/mL (25 mg/2.5 mL) Solution For Injection (Iv)Amber glass ampoule x 2.5 mL (Box of 5's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Korea
Marcburg Philippines Inc.
DR-XY41368
Jul 26, 2028
Atracalmsaph-AltAtracurium Besilate
10 mg/mL (25 mg/2.5 mL) (50 mg/5 mL) Solution For Injection (IV)2.5 Ml & 5 Ml Usp Type I Clear Glass Ampoule
Rx
Althea Pharma Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-19024
Oct 19, 2031
Atracare-StarAtracurium Besilate
10 mg/mL Solution for Injection (IV)Type I amber glass ampoule x 5 mL (Box of 5’s)
Rx
Farbe Firma Pvt. Ltd.India
Twostar Pharmaceutical TradingImporter: AMB HK Enterprises Inc.
DRP-13799-02
May 5, 2028
AtracorAtracurium Besilate
10 mg/mL Solution for I.V Injection3 mL USP Type I glass ampoule x 2.5 mL (Box of 10's)
Rx
Hana Pharmaceutical Co., Ltd.Republic of Korea
Endure Medical, Inc.
DRP-3131
Mar 5, 2028
AtracureAtracurium Besilate
10 mg / mL Solution for Injection (IV)Type I amber glass ampoule x 5 mL (Box of 5's)
Rx
Farbe Firma Pvt. Ltd.India
Curasave PharmaImporter: AMB HK Enterprises Inc.
DRP-13799-01
May 5, 2028
AtracurinAtracurium Besilate
10mg/mL Solution for Injection (IV)3mL Capacity - Type I Clear Glass Ampoule x 2.5 mL (Net Content) in Blister Pack (Box 5's)
Rx
Aculife Healthcare Pvt. Ltd.India
Blue Global (Fze)
DRP-18344
Jun 18, 2031
ATRACUROLLEN-BAtracurium Besilate
10 mg/mL (25 mg/2.5 mL) (50 mg/5 mL) Solution For Injection (IV)Type I Clear Glass Ampoule in PVC Tray x 2.5 mL and 5 mL (Box of 5's)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-18942
Oct 6, 2031
AtracursaphAtracurium Besilate
10mg/mL Solution for Injection (IV)USP Type I Clear Glass Ampoule x 2.5 mL and 5 mL (Box of 5's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12739
Sep 29, 2027
AtragetAtracurium Besilate
10 mg/mL Solution for Injection IV)3 mL-capacity (2.5 mL-net content) clear glass ampoule in PVC tray x 5's (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
2MG Incorporated
DRP-17311
Nov 14, 2030
ATRASTARATRACURIUM BESILATE
10 mg/mL Solution for Injection (IV)3 mL-Capacity (2.5 mL-net content) clear glass ampoule in PVC tray x 5's (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block B)India
Twostar Pharmaceutical TradingImporter: 2MG Incorporated
DRP-17311-01
Nov 14, 2030
AtravellAtracurium Besilate
10 mg/mL (25 mg/2.5 mL) Solution for Injection (I.V.)USP Type I Clear Glass Ampoule x 2.5 mL Box of 5's
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY43285
Mar 11, 2029
AtravellAtracurium Besilate
10 mg/mL (50 mg/5 mL) Solution for Injection (I.V.)USP Type I Clear Glass Ampoule x 5 mL (Box of 5's)
Rx
PT Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY43283
Mar 11, 2029
AtravinAtracurium Besilate
10 mg/mL Solution for Injection (IV)3 mL-capacity (2.5 mL-net content) clear glass ampoule in PVC tray x 5's (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block B)India
MDB Pharma TradingImporter: 2MG Incorporated
DRP-17311-02
Nov 14, 2030
BecuriumAtracurium (as besilate)
10 mg/mL (25 mg/2.5 mL) Solution for IV Injection/Infusion3 mL-capacity USP Type I Clear Colorless Glass Ampoule (2.5 mL net content) [Box of 10's]
Rx
Mefar llac Sanayii A.S.Turkey
Ambica International CorporationTrader: Pharmada Ilac San. Ve tic, A.S.
DRP-12915
Nov 3, 2027
CuranAtracurium besilate
10 mg/mL (25 mg/2.5 mL) Solution for Injection (I.V.)2.5 mL (net content) in 3 mL-capacity USP Type I amber colored glass ampoule in transparent PVC tray x 5 ampoules (box of 10 ampoules)
Rx
Divine Laboratories Pvt. Ltd.India
Despina Pharma, Inc.
DRP-15250
May 31, 2029
DynacuriumAtracurium besilate
10 mg/mL Solution for Injection (IV)USP Type I Glass Ampoule x 2.5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Dynasty PharmaceuticalsImporter: Ambica International Corporation
DRP-7642-03
Oct 8, 2029
KabitranAtracurium Besilate
10mg/mL Solution for Injection (IV)Type I glass ampoule (Box of 5 ampoules x 2.5 mL; Box of 5 ampoules x 5 mL)
Rx
PT. Ethica Industri Farmasi (PT. Ethica)Indonesia
Fresenius Kabi Philippines, Inc.
DR-XY48507
Nov 28, 2027
RatracurAtracurium Besilate
10 mg/mL (25 mg/2.5 mL and 50 mg/5 mL) Solution for IV InfusionUSP Type I clear glass ampoule x 2.5 mL and 5 mL in a PVC plastic tray x 5's (Box of 5's)
Rx
Jiangsu Ruinian Quianjin Pharmaceutical Co., Ltd.China
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-17667
Feb 13, 2031
Relaxium-ABAtracurium (As Besilate)
10 mg/mL (25 mg/ 2.5 mL) Solution for Injection (I.V.)3 mL capacity (2.5 mL net content) USP Type I clear and colorless glass ampoule with blue snap-off ring (Box of 10's)
Rx
Gland Pharma LimitedIndia
Biocare Lifesciences, Inc.
DRP-11186
Feb 16, 2027
TracriumAtracurium Besylate
10 mg/mL Solution for Injection (IV)2.5 mL Type I ampoule (Box of 5's)
Rx
Aspen SVP (Pty) Ltd.Africa
Aspen Philippines Inc.
DRP-14016
Jun 9, 2028
TracubestAtracurium besilate
10 mg/mL Solution for Injection (IV)USP Type I Glass Ampoule x 2.5 mL and 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-7642-01
Oct 8, 2029
TroycuriumAtracurium Besilate
10mg/ml (25mg / 2.5ml) Solution for Injection (I.V.)USP Type I amber glass ampoule with red One-Point-Count (OPC) x 2.5ml (Box of 5's)
Rx
Troikaa Pharmaceuticals LimitedIndia
Troikaa Pharmaceuticals Philippines, Inc.
DR-XY47005
Aug 10, 2030
VetriumAtracurium Besilate
10 mg/mL Solution For Injection (I.V.)Type I amber glass ampoule x 5 mL (Box of 5's)
Rx
Farbe FirmaIndia
AMB HK Enterprises Inc.
DRP-13799
May 5, 2028
(no brand name)Atracurium Besilate
10 mg/mL (25 mg/2.5 mL and 50 mg/5 mL) Solution for Injection for I.V. InfusionUSP Type I colorless glass ampoule x 2.5 mL and 5 mL (net content). Box of 10's.
Rx
Siegfried Hameln GmbHGermany
Enlife Global Inc.
DRP-11259
Feb 18, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS ATRACURIUM SHOULD BE USED ONLY BY THOSE SKILLED IN AIRWAY MANAGEMENT AND RESPIRATORY SUPPORT. EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE FOR ENDOTRACHEAL INTUBATION AND SUPPORT OF VENTILATION, INCLUDING ADMINISTRATION OF POSITIVE PRESSURE OXYGEN. ADEQUACY OF RESPIRATION MUST BE ASSURED THROUGH ASSISTED OR CONTROLLED VENTILATION.

ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. DO NOT GIVE ATRACURIUM BESYLATE BY INTRAMUSCULAR ADMINISTRATION. Atracurium has no known effect on consciousness, pain threshold, or cerebration. It should be used only with adequate anesthesia. Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle.

Depending on the resultant pH of such mixtures, atracurium may be inactivated and a free acid may be precipitated. Atracurium besylate injection 10 mL multiple dose vials contain benzyl alcohol. In neonates, benzyl alcohol has been associated with an increased incidence of neurological and other complications which are sometimes fatal.

Atracurium besylate 5 mL single use vials do not contain benzyl alcohol (see PRECAUTIONS, Pediatric Use). Anaphylaxis Severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate, have been reported. These reactions have in some cases been life-threatening and fatal. Due to the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken.

Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. Risk of Death Due to Medication Errors Administration of atracurium besylate injection results in paralysis, which may lead to respiratory arrest and death; this progression may be more likely to occur in a patient for whom it is not intended.

Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings. If another healthcare provider is administering the product, ensure that the intended dose is clearly labeled and communicated.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by atracurium besylate. Atracurium should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Observed in Controlled Clinical Studies Atracurium was well tolerated and produced few adverse reactions during extensive clinical trials. Most adverse reactions were suggestive of histamine release. In studies including 875 patients, atracurium was discontinued in only one patient (who required treatment for bronchial secretions) and six other patients required treatment for adverse reactions attributable to atracurium (wheezing in one, hypotension in five).

Of the five patients who required treatment for hypotension, three had a history of significant cardiovascular disease. The overall incidence rate for clinically important adverse reactions, therefore, was 7/875 or 0.8%. Table 1 includes all adverse reactions reported attributable to atracurium during clinical trials with 875 patients.

Table 1: Percent of Patients Reporting Adverse Reactions * Includes the recommended initial dosage range for most patients. Adverse Reaction Initial Atracurium Dose (mg/kg) 0.00-0.30 (n = 485) 0.31-0.50* (n = 366) ≥0.60 (n = 24) Total (n = 875) Skin Flush 1.0% 8.7% 29.2% 5.0% Erythema 0.6% 0.5% 0% 0.6% Itching 0.4% 0% 0% 0.2% Wheezing/Bronchial Secretions 0.2% 0.3% 0% 0.2% Hives 0.2% 0% 0% 0.1% Most adverse reactions were of little clinical significance unless they were associated with significant hemodynamic changes.

Table 2 summarizes the incidences of substantial vital sign changes noted during atracurium clinical trials with 530 patients, without cardiovascular disease, in whom these parameters were assessed. Table 2: Percent of Patients Showing >30% Vital Sign Changes Following Administration of Atracurium * Includes the recommended initial dosage range for most patients.

Vital Sign Change Initial Atracurium Dose (mg/kg) 0.00-0.30 (n = 365) 0.31-0.50* (n = 144) ≥0.60 (n = 21) Total (n = 530) Mean Arterial Pressure Increase 1.9% 2.8% 0% 2.1% Decrease 1.1% 2.1% 14.3% 1.9% Heart Rate Increase 1.6% 2.8% 4.8% 2.1% Decrease 0.8% 0% 0% 0.6% Observed in Clinical Practice Based on initial clinical practice experience in approximately 3 million patients who received atracurium in the U.S. and in the United Kingdom, spontaneously reported adverse reactions were uncommon (approximately 0.01% to 0.02%). The following adverse reactions are among the most frequently reported, but there are insufficient data to support an estimate of their incidence: General: Allergic reactions (anaphylactic or anaphylactoid responses) which, in rare instances, were severe (e.g., cardiac arrest) Musculoskeletal: Inadequate block, prolonged block Cardiovascular: Hypotension, vasodilatation (flushing), tachycardia, bradycardia Respiratory: Dyspnea, bronchospasm, laryngospasm Integumentary: Rash, urticaria, reaction at injection site There have been rare spontaneous reports of seizures in ICU patients following long-term infusion of atracurium to support mechanical ventilation.

There are insufficient data to define the contribution, if any, of atracurium and/or its metabolite laudanosine (see PRECAUTIONS, Long-Term Use in Intensive Care Unit (ICU)). There have been post-marketing reports of severe allergic reactions (anaphylactic and anaphylactoid reactions) associated with use of neuromuscular blocking agents, including atracurium besylate.

These reactions, in some cases, have been life-threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see WARNINGS and PRECAUTIONS). To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Percent of Patients Reporting Adverse Reactions
* Includes the recommended initial dosage range for most patients.
Adverse ReactionInitial Atracurium Dose (mg/kg)
0.00-0.30 (n = 485) 0.31-0.50* (n = 366) ≥0.60 (n = 24) Total (n = 875)
Skin Flush 1.0% 8.7% 29.2% 5.0%
Erythema 0.6% 0.5% 0% 0.6%
Itching 0.4% 0% 0% 0.2%
Wheezing/Bronchial Secretions 0.2% 0.3% 0% 0.2%
Hives 0.2% 0% 0% 0.1%
Table 2: Percent of Patients Showing >30% Vital Sign Changes Following Administration of Atracurium
* Includes the recommended initial dosage range for most patients.
Vital Sign ChangeInitial Atracurium Dose (mg/kg)
0.00-0.30 (n = 365) 0.31-0.50* (n = 144) ≥0.60 (n = 21) Total (n = 530)
Mean Arterial Pressure
Increase 1.9% 2.8% 0% 2.1%
Decrease 1.1% 2.1% 14.3% 1.9%
Heart Rate
Increase 1.6% 2.8% 4.8% 2.1%
Decrease 0.8% 0% 0% 0.6%

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects: Pregnancy Category C Atracurium besylate has been shown to be potentially teratogenic in rabbits when given in doses up to approximately one-half the human dose. There are no adequate and well-controlled studies in pregnant women. Atracurium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Atracurium besylate was administered subcutaneously on days 6 through 18 of gestation to non-ventilated Dutch rabbits. Treatment groups were given either 0.15 mg/kg once daily or 0.10 mg/kg twice daily. Lethal respiratory distress occurred in two 0.15 mg/kg animals and in one 0.10 mg/kg animal, with transient respiratory distress or other evidence of neuromuscular block occurring in 10 of 19 and in 4 of 20 of the 0.15 mg/kg and 0.10 mg/kg animals, respectively.

There was an increased incidence of certain spontaneously occurring visceral and skeletal anomalies or variations in one or both treated groups when compared to non-treated controls. The percentage of male fetuses was lower (41% vs. 51%) and the post-implantation losses were increased (15% vs. 8%) in the group given 0.15 mg/kg once daily when compared to the controls; the mean numbers of implants (6.5 vs. 4.4) and normal live fetuses (5.4 vs. 3.8) were greater in this group when compared to the control group.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when atracurium besylate is administered to a nursing woman.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The elimination half-life is approximately 20 minutes.

Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which atracurium represented only a minor fraction.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Atracurium besylate is a nondepolarizing skeletal muscle relaxant. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by atracurium is approximately one-third to one-half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses.

As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing atracurium doses. The ED 95 (dose required to produce 95% suppression of the muscle twitch response with balanced anesthesia) has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies).

An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection.

Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane's potentiating effect (approximately 20%) is marginal (see DOSAGE AND ADMINISTRATION).

Repeated administration of maintenance doses of atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

After an initial dose of 0.4 to 0.5 mg/kg under balanced anesthesia, the first maintenance dose (suggested maintenance dose is 0.08 to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. Once recovery from atracurium's neuromuscular blocking effects begins, it proceeds more rapidly than recovery from d-tubocurarine, metocurine, and pancuronium.

Regardless of the atracurium dose, the time from start of recovery (from complete block) to complete (95%) recovery is approximately 30 minutes under balanced anesthesia, and approximately 40 minutes under halothane, enflurane or isoflurane. Repeated doses have no cumulative effect on recovery rate. Reversal of neuromuscular block produced by atracurium can be achieved with an anticholinesterase agent such as neostigmine, edrophonium, or pyridostigmine, in conjunction with an anticholinergic agent such as atropine or glycopyrrolate.

Under balanced anesthesia, reversal can usually be attempted approximately 20 to 35 minutes after an initial atracurium besylate dose of 0.4 to 0.5 mg/kg, or approximately 10 to 30 minutes after a 0.08 to 0.10 mg/kg maintenance dose, when recovery of muscle twitch has started. Complete reversal is usually attained within 8 to 10 minutes of the administration of reversing agents.

Rare instances of breathing difficulties, possibly related to incomplete reversal, have been reported following attempted pharmacologic antagonism of atracurium-induced neuromuscular block. As with other agents in this class, the tendency for residual neuromuscular block is increased if reversal is attempted at deep levels of block or if inadequate doses of reversal agents are employed.

The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. THE DURATION OF NEUROMUSCULAR BLOCK PRODUCED BY ATRACURIUM BESYLATE DOES NOT CORRELATE WITH PLASMA PSEUDOCHOLINESTERASE LEVELS AND IS NOT ALTERED BY THE ABSENCE OF RENAL FUNCTION.

This is consistent with the results of in vitro studies which have shown that atracurium is inactivated in plasma via two nonoxidative pathways: ester hydrolysis, catalyzed by nonspecific esterases; and Hofmann elimination, a nonenzymatic chemical process which occurs at physiological pH. Some placental transfer occurs in humans.

Radiolabel studies demonstrated that atracurium undergoes extensive degradation in cats, and that neither kidney nor liver plays a major role in this elimination. Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which atracurium represented only a minor fraction.

The metabolites in bile and urine were similar, including products of Hofmann elimination and ester hydrolysis. Elderly patients may have slightly altered pharmacokinetic parameters compared to younger patients, with a slightly decreased total plasma clearance which is offset by a corresponding increase in volume of distribution.

The net effect is that there has been no significant difference in clinical duration and recovery from neuromuscular block observed between elderly and younger patients receiving atracurium besylate. Atracurium is a less potent histamine releaser than d-tubocurarine or metocurine. Histamine release is minimal with initial atracurium besylate doses up to 0.5 mg/kg, and hemodynamic changes are minimal within the recommended dose range.

A moderate histamine release and significant falls in blood pressure have been seen following 0.6 mg/kg of atracurium besylate. The histamine and hemodynamic responses were poorly correlated. The effects were generally short-lived and manageable, but the possibility of substantial histamine release in sensitive individuals or in patients in whom substantial histamine release would be especially hazardous (e.g., patients with significant cardiovascular disease) must be considered.

It is not known whether the prior use of other nondepolarizing neuromuscular blocking agents has any effect on the activity of atracurium. The prior use of succinylcholine decreases by approximately 2 to 3 minutes the time to maximum block induced by atracurium besylate, and may increase the depth of block. Atracurium should be administered only after a patient recovers from succinylcholine-induced neuromuscular block.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Atracurium 10 mg/mL, 2.5 mL Ampule₱58.77–₱228.00Reference ₱77.84per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Atracurium (as besilate)
PNF listingInj.: 10 mg/mL, 2.5 mL and 5 mL ampul (IV)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Atracurium Besylate · Meitheal Pharmaceuticals Inc. [US FDA-approved label, version 5, December 4, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efe90ee2-fe9e-421f-9e54-2961085d3b12
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .